Compare Arista Networks Inc (ANET) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arista Networks Inc vs BioNTech SE - ADR — how do they compare? Arista Networks Inc trades at $210.79 (market cap $249.53B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: Arista Networks Inc is far larger — about 10.7× BioNTech SE - ADR's market cap, and Arista Networks Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ANET | BNTX | |
|---|---|---|
Market Cap | $249.53B | $23.31B |
Sector | Technology | Health |
52-Week High | $197.85 | $119.34 |
52-Week Low | $116.13 | $83.89 |
Enterprise Value | $236.19B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $208.47, up 8.85% in the last session, reflecting strong momentum amid robust AI-driven demand. The stock shows bullish technical signals with consistent earnings beats and accelerating revenue growth, reaching $9.01B in 2025. Analyst consensus remains overwhelmingly positive with a $252.25 price target, though valuation multiples appear elevated at P/E 62.61 and P/S 23.94. Recent news highlights insider selling but maintains confidence in the company's AI networking leadership.
Outlook remains favorable given hyperscaler capex expansion and Ethernet market share gains, but risks include premium valuation compression and competitive pressures. The stock offers growth exposure to AI infrastructure with solid execution, though investors should weigh high expectations against potential volatility.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
